GlassScriptPhysician profile
Toniya Singh
NPI 1629082847
$21,922.93
in general payments reported to CMS, 2019-2025
44 companies · $5,744 in 2025
The $5,744 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $3,931 · 2021: $1,979 · 2022: $4,208 · 2023: $1,771 · 2024: $3,268 · 2025: $5,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,000 · Food and Beverage: $4,437 · Travel and Lodging: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,000.00 |
| Food and Beverage | $4,436.58 |
| Travel and Lodging | $345.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9,129.44 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $3,738.23 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $2,077.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $728.98 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $638.69 | 2019-2024 | Jardiance |
| Pfizer INC. | $582.29 | 2019-2025 | |
| Amgen INC. | $524.55 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $485.55 | 2020-2025 | Wainua, Farxiga |
| Abiomed | $381.41 | 2024-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $363.14 | 2019-2024 | |
| Esperion Therapeutics, INC. | $359.08 | 2020-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $295.11 | 2021-2024 | Verquvo |
| Amarin Pharma, INC. | $233.44 | 2019-2022 | |
| Biosense Webster, INC. | $216.89 | 2022-2025 | Qdot Micro |
| Impulse Dynamics (USA) INC. | $206.85 | 2023 | Optimizer |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toniya Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.